HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/3/H1432    most recent 00038.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Weihrauch, D. Articles by Pritchard, K. A. Search for Related Content PubMed PubMed Citation Articles by Weihrauch, D. Articles by Pritchard, K. A.

Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice

¹Cardiovascular Center, ²Children's Research Institute, ³Department of Pharmacology and Toxicology, ⁴Departments Pathology, ⁵Anesthesiology, ⁶Surgery, Division of Pediatric Surgery, ⁷Department of Medicine, Division of Rheumatology and Medical College of Wisconsin, Milwaukee, Wisconsin

Submitted 10 January 2007 ; accepted in final form 11 May 2007

Systemic sclerosis (scleroderma, SSc) is an autoimmune, connective tissue disorder that is characterized by impaired vascular function, increased oxidative stress, inflammation of internal organs, and impaired angiogenesis. Tight skin mice (Tsk^–/+) have a defect in fibrillin-1, resulting in replication of many of the myocardial and vascular features seen in humans with SSc. D-4F is an apolipoprotein A-I (apoA-I) mimetic that improves vascular function in diverse diseases such as hypercholesterolemia, influenza, and sickle cell disease. Tsk^–/+ mice were treated with either phosphate-buffered saline (PBS) or D-4F (1 mg·kg^–1·day^–1 for 6–8 wk). Acetylcholine and flow-induced vasodilation were examined in facialis arteries. Proinflammatory HDL (p-HDL) in murine and human plasma samples was determined by the cell-free assay. Angiostatin levels in murine and human plasma samples were determined by Western blot analysis. Hearts were examined for changes in angiostatin and autoantibodies against oxidized phosphotidylcholine (ox-PC). Angiogenic potential in thin sections of murine hearts was assessed by an in vitro vascular endothelial growth factor (VEGF)-induced endothelial cell (EC) tube formation assay. D-4F improved endothelium-, endothelial nitric oxide synthase-dependent, and flow-mediated vasodilation in Tsk^–/+ mice. Tsk^–/+ mice had higher plasma p-HDL and angiostatin levels than C57BL/6 mice, as did SSc patients compared with healthy control subjects. Tsk^–/+ mice also had higher triglycerides than C57BL/6 mice. D-4F reduced p-HDL, angiostatin, and triglycerides in the plasma of Tsk^–/+ mice. Tsk^–/+ hearts contained notably higher levels of angiostatin and autoantibodies against ox-PC than those of control hearts. D-4F ablated angiostatin in Tsk^–/+ hearts and reduced autoantibodies against ox-PC by >50% when compared with hearts from untreated Tsk^–/+ mice. Angiogenic potential in Tsk^–/+ hearts was increased only when the Tsk^–/+ mice were treated with D-4F (1 mg·kg^–1·day^–1, 6–8 wk), and cultured sections of hearts from the D-4F-treated Tsk^–/+ micewere incubated with D-4F (10 µg/ml, 5–7 days). Failure to treat the thin sections of hearts and Tsk^–/+ mice with D-4F resulted in loss of VEGF-induced EC tube formation. D-4F improves vascular function, decreases myocardial inflammation, and restores angiogenic potential in the hearts of Tsk^–/+ mice. As SSc patients have increased plasma p-HDL and angiostatin levels similar to the Tsk^–/+ mice, D-4F may be effective at treating vascular complications in patients with SSc.

systemic sclerosis; angiogenesis

This article has been cited by other articles:

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman HDL as a Biomarker, Potential Therapeutic Target, and Therapy Diabetes, December 1, 2009; 58(12): 2711 - 2717. [Full Text] [PDF]

				M. Navab, S. T. Reddy, B. J. Van Lenten, G. M. Anantharamaiah, and A. M. Fogelman The role of dysfunctional HDL in atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S145 - S149. [Abstract] [Full Text] [PDF]

				S. Patel, B. G. Drew, S. Nakhla, S. J. Duffy, A. J. Murphy, P. J. Barter, K.-A. Rye, J. Chin-Dusting, A. Hoang, D. Sviridov, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol., March 17, 2009; 53(11): 962 - 971. [Abstract] [Full Text] [PDF]

				B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311. [Abstract] [Full Text] [PDF]

				A. C. Frei, Y. Guo, D. W. Jones, K. A. Pritchard Jr, K. A. Fagan, N. Hogg, and N. J. Wandersee Vascular dysfunction in a murine model of severe hemolysis Blood, July 15, 2008; 112(2): 398 - 405. [Abstract] [Full Text] [PDF]

				A. Dooley, S. Y. Low, A. Holmes, A. G. Kidane, D. J. Abraham, C. M. Black, and K. R. Bruckdorfer Nitric oxide synthase expression and activity in the tight-skin mouse model of fibrosis Rheumatology, March 1, 2008; 47(3): 272 - 280. [Abstract] [Full Text] [PDF]

				G. M. Buga, J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M. Navab, S. T. Reddy, G. M. Anantharamaiah, et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet J. Lipid Res., January 1, 2008; 49(1): 192 - 205. [Abstract] [Full Text] [PDF]